As of Thursday, May 15, iTeos Therapeutics, Inc.’s ITOS share price has surged by 5.79%, which has investors questioning if ...

Recently, a new class of therapeutics that disable the neonatal Fc receptor (FcRn), which protects IgG from degradation, has emerged to treat IgG-mediated autoimmune disease. 4,5 Here, we review ...

Designed with the company's IMPACT platform, the antibody 'agonises' the programmed cell death protein-1 (PD-1) and Fc-gamma receptor IIb (FcγRIIb). FcγRIIb and PD‑1 are said to be key ...

Previous studies established defective Fc receptor mediated clearance in patients with systemic lupus erythematosis (SLE), a disorder associated with circulating immune complexes (CIC).

As of Wednesday, May 07, iTeos Therapeutics, Inc.’s ITOS share price has dipped by 5.74%, which has investors questioning if this is right time to buy.